CAS: 78439-06-2; Ceftazidime Pentahydrate

该化合物是一种主要用于治疗克氏阴性细菌感染的抗生素,其特点是能够抑制细菌细胞壁合成,使其对各种病原体有效,包括Pseudomonas aeruginosa.五氢酸二甲酯形式表明,该化合物含有五种水分子,可影响其溶解性和稳定性.二硝基苯通常通过注射方式施用,并经常用于医院的严重感染环境,包括免疫复合病人.其化学结构有一个乙状乳环,这是其抗菌活动必不可少的.该化合物一般都受到良好的调试,但与所有抗生素一样,可产生副作用,包括过敏反应和胃肠扰动.由于抗生素抗药性的出现,其使用往往受到感应测试的引导,以确保对特定细菌菌株的有效性.

结构式图片

欧盟法规

C&L通报REACH预注册

合成工艺路线路线简述

    头孢他啶 在 Ceftazidime Pentahydrate,水,丙酮体系中,用 甲酸作为反应溶剂,反应 5.0H,以to Give 20.8 G Of Ceftazidime Pentahydrate的收率获得ceftazidime Pentahydrate
    参考文献:Crystallization Process For Ceftazidime Derivative
    标题:Crystallization Process For Ceftazidime Derivative
    摘要:盐酸头孢他啶五水合物是通过将头孢他啶的水溶液酸化至最佳成核ph值约为4.0至4.7,并在结晶过程中保持最佳ph值,从而以纯化结晶形式获得的.所得的晶体产物在应力条件下表现出增强的聚合物稳定性.

    海关参考信息

    专利信息


    专利号:US-8017776-B2
    优先权日:2003-07-15
    标题 :Methods for synthesis of acyloxyalkyl compounds
    发明人:BHAT LAXMINARAYAN; GALLOP MARK A
    权利人:XENOPORT INC
    摘要:Disclosed herein are methods for synthesizing 1-(acyloxy)-alkyl prodrug derivatives of drugs through oxidation of 1-acyl-alkyl derivatives of drugs under anhydrous reaction conditions. The methods typically proceed stereospecifically, in high yield, do not require the use of activated intermediates and/or toxic compounds and are readily amenable to scale-up.

    专利号:US-10443047-B2
    优先权日:2014-05-01
    标题 :Increasing cellular lipid production by increasing the activity of diacylglycerol acyltransferase and decreasing the activity of triacylglycerol lipase
    发明人:TSAKRAKLIDES VASILIKI; BREVNOVA ELENA E
    权利人:NOVOGY INC
    摘要:Disclosed are methods and compositions for increasing the triacylglycerol content of a cell by up-regulating diacylglycerol acyltransferase and down-regulating triacylglycerol lipase. In some embodiments, a DGA1 protein is expressed and a native TGL3 gene is knocked out, thereby increasing the synthesis of triacylglycerol and decreasing its consumption, respectively.

    专利号:US-8143437-B2
    优先权日:2002-02-19
    标题:Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
    发明人:GALLOP MARK A; XIANG JIA-NING; YAO FENMEI; BHAT LAXMINARAYAN; ZHOU CINDY X
    权利人:GALLOP MARK A; XIANG JIA-NING; YAO FENMEI; BHAT LAXMINARAYAN; ZHOU CINDY X; XENOPORT INC
    摘要:The present invention provides a method for synthesizing 1-(acyloxy)-alkyl derivatives from 1-acyl-alkyl derivatives, which typically proceeds stereospecifically, in high yield, does not require the use of activated intermediates and/or toxic compounds and is readily amendable to scale-up. The current invention also provides 1-acyl-alkyl derivatives of known drug components and methods for synthesizing these 1-acyl-alkyl derivatives.

    专利号:US-7452990-B2
    优先权日:2002-12-26
    标题 :Intermediates for synthesis of cephalosporins and process for preparation of such intermediates
    发明人:DATTA DEBASHISH; DANTU MURALIKRISHNA; MISHRA BRIJKISHORE; SHARMA POLLEPEDDI LAKSHMI NARAYANA
    权利人:LUPIN LTD
    摘要:A novel 4-halo-2-oxyimino-3-oxo butyric acid-N,N-dimethyl formiminium chloride chlorosulfate of formula (I) useful in the preparation of cephalosporin antibiotics n nwhereinn n X is chlorine or bromine; R is hydrogen, C 1-4 alkyl group, an easily removable hydroxyl protective group, —CH 2 COOR 5 , or —C(CH 3 ) 2 COOR 5 , wherein R 5 is hydrogen or an easily hydrolysable ester group. The compound of formula (I) is prepared by reacting 4-halo-2-oxyimino-3-oxobutyric acid of formula (IV 1 ), n nwherein X, R and R 5 are as defined above, with N,N-dimethylformiminium chloride chlorosulphate of formula (VII)n n nin an organic solvent at a temperature ranging from −30° C. to −15° C. The cephalosporins that may be prepared from the intermediate include cefdinir, cefditoren pivoxil, cefepime, cefetamet pivoxil, cefixime, cefmenoxime, cefodizime, cefoselis, cefotaxime, cefpirome, cefpodoxime proxetil, cefquinome, ceftazidime, cefteram pivoxil, ceftiofur, ceftizoxime, ceftriaxone and cefuzonam.

    专利号:US-9650407-B2
    优先权日:2011-11-02
    标 题 :Reprogramming of cellular adhesion
    发明人:GARTNER ZEV JORDAN; SELDEN NICHOLAS SCOTT; TODHUNTER MICHAEL E; LIANG SAMANTHA ISABEL; WEBER ROBERT JOSEPH; JEE NOEL YOUNGHO; LIU JENNIFER S
    权利人:UNIV CALIFORNIA
    摘要:Disclosed are membrane-anchored polynucleotides, and compositions comprising the membrane-anchored polynucleotides. Also disclosed are the processes for the synthesis of these compounds, compositions comprising such compounds, and the use of such compounds and compositions in research and therapeutic applications.

    专利号:US-2023364251-A1
    优先权日:2020-08-06
    标 题:Methods for the synthesis of protein-drug conjugates
    发明人:BORCHARDT ALLEN; HUGHES ROBERT MICHAEL
    权利人:CIDARA THERAPEUTICS INC
    摘要:The present invention relates to intermediates and methods for synthesizing protein-drug conjugates that can be used for the treatment of diseases and related conditions.
    海宁凤鸣叶绿素有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.fengming.com
    电话: 86-573-87013227 87533318👤
    📞海宁凤鸣叶绿素有限公司 ⚠️参考联系方式

    销售电话:86-573-87013227 87533318
    邮箱:postmaster@fengming.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    苏州中联化学制药有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.uni-cent.com
    电话: 0086 (512) 6362-4672👤
    📞苏州中联化学制药有限公司 ⚠️参考联系方式

    销售电话:0086 (512) 6362-4672
    邮箱:sales@uni-cent.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:江苏省吴江市黎里镇交通东路9号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Jones TE, Selby PR, Mellor CS, Cheam DB. Ceftazidime stability and pyridine toxicity during continuous i.v. infusion. Am J Health Syst Pharm. 2019 Feb 1;76(4):200-205. doi: 10.1093/ajhp/zxy035. Review. pii: e02187-18. doi: 10.1128/AAC.02187-18. Print 2019 Apr. Review.
    3: Giri P, Patel H, Srinivas NR. Review of Clinical Pharmacokinetics of Avibactam, A Newly Approved non-β lactam β-lactamase Inhibitor Drug, In Combination Use With Ceftazidime. Drug Res (Stuttg). 2019 May;69(5):245-255. doi: 10.1055/a-0748-5548. Epub 2018 Oct 8. Review. doi: 10.1007/s40262-018-0705-y. Review. doi: 10.1016/j.ijantimicag.2018.07.004. Epub 2018 Aug 31. Review. Available from http://www.ncbi.nlm.nih.gov/books/NBK501420/ Available from http://www.ncbi.nlm.nih.gov/books/NBK500953/ doi: 10.1007/s40265-018-0902-x. Review. doi: 10.1080/14787210.2018.1453807. Epub 2018 Mar 21. Review. doi: 10.2174/1573396314666180308150908. Review. doi: 10.1080/17425255.2018.1434142. Epub 2018 Jan 31. Review. doi: 10.1007/s15010-017-1096-y. Epub 2017 Nov 7. Review. Review. doi: 10.18433/J3X31R. Review. eCollection 2016. Review.
    16: Buckman SA, Krekel T, Muller AE, Mazuski JE. Ceftazidime-avibactam for the treatment of complicated intra-abdominal infections. Expert Opin Pharmacother. 2016 Dec;17(17):2341-2349. Epub 2016 Oct 31. Review. doi: 10.2147/DDDT.S110946. eCollection 2016. Review.

    合成参考文献


    摘要:Iyakuhin Kenkyu. Study of Medical Supplies., 17(1106), 1986
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知